SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla spurts on inking MoU with Russian firm for HIV, Hepatitis C drugs

20 Jun 2016 Evaluate

Cipla is currently trading at Rs. 487.40, up by 1.85 points or 0.38% from its previous closing of Rs 485.55 on the BSE.

The scrip opened at Rs. 486.00 and has touched a high and low of Rs. 489.80 and Rs. 484.65 respectively. So far 28666 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 748.00 on 17-Aug-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.

Last one week high and low of the scrip stood at Rs. 492.00 and Rs. 465.20 respectively. The current market cap of the company is Rs. 39053.43 crore.

The promoters holding in the company stood at 36.78%, while Institutions and Non-Institutions held 34.17% and 27.13% respectively.

Cipla, a global pharmaceutical company has signed a Memorandum of Understanding (MoU) with Russia’s National Immunobiological Company to innovative antiviral medical products for HIV and Hepatitis C treatment and to technology transfer and active pharmaceutical ingredients (API) manufacturing. New drugs production will help to change therapeutic regimens and substantially increase availability of drugs for Russian patients. By 2019 total market share for anti-HIV drugs will increase to 60%.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.

Cipla Share Price

1235.95 -2.35 (-0.19%)
20-Apr-2026 11:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.70
Dr. Reddys Lab 1236.80
Cipla 1235.95
Zydus Lifesciences 939.75
Lupin 2328.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×